n(g),n(g')-dimethyl-l-arginine has been researched along with Kidney Diseases in 61 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 9.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| " Asymmetric dimethylarginine (ADMA) is increased in diabetes mellitus, kidney disease, and hypertension." | 7.79 | Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. ( Hsu, CN; Huang, LT; Lee, CT; Lee, WC; Lin, CY; Tain, YL, 2013) |
| "Ramipril was given (5 mg daily for 12 weeks), and circulating ADMA, soluble Fas (sFas), myostatin and endothelial function [flow-mediated vasodilation (FMD); ultrasound)] were measured." | 5.36 | Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? ( Axelsson, J; Caglar, K; Cayci, T; Eyileten, T; Kilic, S; Oguz, Y; Saglam, M; Sonmez, A; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2010) |
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 5.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| " Here, we summarize some molecular mechanisms leading from hyperhomocysteinemia, elevated asymmetric dimethylarginine (ADMA) and advanced glycation end products (AGEs)-modified proteins to atherogenic endothelial phenotype and offer a model of endothelial dysfunction based on the interconnectedness of diverse functions." | 4.82 | Endothelial cell dysfunction: the syndrome in making. ( Brodsky, SV; Chen, J; Goligorsky, MS; Li, H; O'Riordan, E; Smirnova, I, 2005) |
| " Asymmetric dimethylarginine (ADMA) is increased in diabetes mellitus, kidney disease, and hypertension." | 3.79 | Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. ( Hsu, CN; Huang, LT; Lee, CT; Lee, WC; Lin, CY; Tain, YL, 2013) |
| " We explored the temporal progression of bile duct ligation (BDL)-induced cholestasis in developing rats, focusing on brain cognition and liver and kidney pathology, to elucidate whether these findings were associated with asymmetric dimethylarginine and oxidative stress alterations." | 3.76 | Bile duct ligation in developing rats: temporal progression of liver, kidney, and brain damage. ( Chen, CC; Hsieh, CS; Huang, LT; Sheen, JM; Tain, YL; Wang, JY, 2010) |
| " However, little information is available about any association between plasma levels of asymmetric dimethylarginine (ADMA), insulin resistance, and CAC." | 3.74 | Coronary artery calcification, ADMA, and insulin resistance in CKD patients. ( Hidekazu, M; Ikee, R; Kobayashi, S; Maesato, K; Mano, T; Ohtake, T; Oka, M, 2008) |
| "The rationale of this study is based on the fact that, both proteinuria and elevated asymmetric dimethyl arginine (ADMA) levels have been linked to the progression of vascular disease." | 3.73 | ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. ( Acikel, C; Bilgi, C; Caglar, K; Cakir, E; Eyileten, T; Kaya, A; Oguz, Y; Oktenli, C; Sonmez, A; Vural, A; Yenicesu, M; Yilmaz, MI; Zoccali, C, 2006) |
| "We assessed blood concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) as well as renal haemodynamics to compare normotensive patients with mild heart failure (n = 12, seven males, 70 +/- 1 years, 72." | 3.72 | Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. ( Bode-Böger, SM; Fliser, D; Graf, S; Haller, H; Kielstein, JT; Klein, G, 2003) |
| ") bioavailability and potentially limit atherosclerosis." | 2.71 | Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. ( Abdulhayoglu, E; Barbato, D; Bustami, R; D'Alecy, LG; Desai, A; Handelman, GJ; Novak, JE; Rajagopalan, S; Saran, R; Warren, JS; Weitzel, W, 2003) |
| "Asymmetric dimethylarginine (ADMA) is a naturally occurring amino acid that reduces the bioavailability of nitric oxide." | 2.44 | Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. ( Kielstein, JT; Zoccali, C, 2008) |
| " The ADMA-mediated regulation of nitric oxide (NO) production is determined by the quantitative bioavailability of intracellular and extracellular ADMA." | 2.44 | Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. ( Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2007) |
| "Endothelial dysfunction due to the reduced bioavailability of nitric oxide (NO) is involved in the course of atherosclerotic cardiovascular disease as well as chronic kidney disease (CKD)." | 2.44 | Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. ( Fukami, K; Matsumoto, Y; Okuda, S; Ueda, S; Yamagishi, SI, 2007) |
| "Intradialytic hypotension is a major complication during hemodialysis session, associated with increased risk of cardiovascular events and mortality." | 1.51 | Intradialytic hypotension: beyond hemodynamics. ( Assaad, S; Chacra, D; Chelala, D; Fares, N; Hajal, J; Joubran, N; Saliba, Y; Sleilaty, G, 2019) |
| "Symmetric dimethylarginine (SDMA) was recently demonstrated to induce reactive oxygen species in monocytes." | 1.37 | Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. ( Barreto, DV; Barreto, FC; Eloot, S; Glorieux, G; Liabeuf, S; Massy, Z; Schepers, E; Vanholder, R, 2011) |
| "Ramipril was given (5 mg daily for 12 weeks), and circulating ADMA, soluble Fas (sFas), myostatin and endothelial function [flow-mediated vasodilation (FMD); ultrasound)] were measured." | 1.36 | Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? ( Axelsson, J; Caglar, K; Cayci, T; Eyileten, T; Kilic, S; Oguz, Y; Saglam, M; Sonmez, A; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2010) |
| " Among patients with ischemic heart disease, low progenitor cell bioavailability and kidney dysfunction are emerging as strong predictors of death and recurrent cardiovascular events." | 1.35 | Asymmetric dimethylarginine and impaired cardiovascular healing. ( Andreotti, F; Coluzzi, G; Marzo, F; Santucci, E, 2009) |
| "Reduced bioavailability of nitric oxide (NO) is thought to play an important role in progression of renal damage." | 1.33 | Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. ( Bode-Böger, SM; Fliser, D; Haller, H; Kielstein, JT; Kronenberg, F; Morath, C; Ritz, E, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (52.46) | 29.6817 |
| 2010's | 27 (44.26) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, Y | 1 |
| Steinbach, SML | 1 |
| Basile, D | 1 |
| Singh, J | 1 |
| Hajal, J | 1 |
| Joubran, N | 1 |
| Sleilaty, G | 1 |
| Chacra, D | 1 |
| Saliba, Y | 1 |
| Assaad, S | 1 |
| Chelala, D | 1 |
| Fares, N | 1 |
| Wu, M | 2 |
| Yuan, M | 1 |
| Wang, Y | 1 |
| Tan, B | 1 |
| Huang, D | 1 |
| Wang, C | 2 |
| Zou, Y | 1 |
| Ye, C | 2 |
| Shi, L | 1 |
| Zhao, C | 1 |
| Wang, H | 1 |
| Lei, T | 1 |
| Liu, S | 1 |
| Cao, J | 1 |
| Lu, Z | 1 |
| Salmas, RE | 1 |
| Gulhan, MF | 1 |
| Durdagi, S | 1 |
| Sahna, E | 1 |
| Abdullah, HI | 1 |
| Selamoglu, Z | 1 |
| Hu, XL | 1 |
| Li, MP | 1 |
| Song, PY | 1 |
| Tang, J | 1 |
| Chen, XP | 1 |
| Lin, P | 1 |
| Li, L | 1 |
| Chen, D | 1 |
| Yang, X | 1 |
| Xu, L | 1 |
| Zhou, B | 1 |
| Zhang, Y | 1 |
| Luo, C | 1 |
| Tain, YL | 3 |
| Lee, WC | 2 |
| Hsu, CN | 2 |
| Huang, LT | 3 |
| Lee, CT | 1 |
| Lin, CY | 1 |
| Günebakmaz, O | 1 |
| Duran, M | 1 |
| Karakaya, E | 1 |
| Tanrıkulu, E | 1 |
| Akpek, M | 1 |
| Ergin, A | 1 |
| Kaya, MG | 1 |
| Schepers, E | 2 |
| Speer, T | 1 |
| Bode-Böger, SM | 6 |
| Fliser, D | 9 |
| Kielstein, JT | 12 |
| Yilmaz, BA | 1 |
| Caliskan, Y | 1 |
| Yilmaz, A | 1 |
| Ozkok, A | 1 |
| Bilge, AK | 1 |
| Deniz, G | 1 |
| Sariyar, M | 1 |
| Yildiz, A | 1 |
| Alpoim, PN | 1 |
| Sousa, LP | 1 |
| Mota, AP | 1 |
| Rios, DR | 1 |
| Dusse, LM | 1 |
| Kobayashi, S | 1 |
| Oka, M | 1 |
| Maesato, K | 1 |
| Ikee, R | 1 |
| Mano, T | 1 |
| Hidekazu, M | 1 |
| Ohtake, T | 1 |
| Nanayakkara, PW | 1 |
| Kiefte-de Jong, JC | 1 |
| ter Wee, PM | 1 |
| Stehouwer, CD | 1 |
| van Ittersum, FJ | 1 |
| Olthof, MR | 1 |
| Teerlink, T | 1 |
| Twisk, JW | 1 |
| van Guldener, C | 1 |
| Smulders, YM | 1 |
| Ueda, S | 4 |
| Matsumoto, Y | 3 |
| Kaida, Y | 1 |
| Okuda, S | 4 |
| Yamagishi, S | 3 |
| Mora-Fernández, C | 1 |
| Jarque, A | 1 |
| Getino, MA | 1 |
| Sánchez, R | 1 |
| Lozano, L | 1 |
| Navarro, JF | 1 |
| Zoccali, C | 9 |
| Mallamaci, F | 1 |
| Kato, GJ | 1 |
| Wang, Z | 1 |
| Machado, RF | 1 |
| Blackwelder, WC | 1 |
| Taylor, JG | 1 |
| Hazen, SL | 1 |
| Nakamura, T | 1 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Kawagoe, Y | 1 |
| Ueda, Y | 1 |
| Suzuki, T | 1 |
| Fukami, K | 3 |
| Abedini, S | 1 |
| Meinitzer, A | 1 |
| Holme, I | 1 |
| März, W | 1 |
| Weihrauch, G | 1 |
| Fellstrøm, B | 1 |
| Jardine, A | 1 |
| Holdaas, H | 1 |
| David, S | 1 |
| Kümpers, P | 1 |
| Lukasz, A | 1 |
| Martens-Lobenhoffer, J | 1 |
| Kliem, V | 1 |
| Haller, H | 6 |
| Yilmaz, MI | 5 |
| Sonmez, A | 4 |
| Saglam, M | 3 |
| Yaman, H | 3 |
| Cayci, T | 1 |
| Kilic, S | 2 |
| Eyileten, T | 4 |
| Caglar, K | 4 |
| Oguz, Y | 3 |
| Vural, A | 4 |
| Yenicesu, M | 3 |
| Axelsson, J | 2 |
| Demirkaya, E | 1 |
| Sheen, JM | 1 |
| Hsieh, CS | 1 |
| Chen, CC | 1 |
| Wang, JY | 1 |
| Marín, M | 1 |
| Máñez, S | 1 |
| Lilitkarntakul, P | 1 |
| Dhaun, N | 1 |
| Melville, V | 1 |
| Blackwell, S | 1 |
| Talwar, DK | 1 |
| Liebman, B | 1 |
| Asai, T | 1 |
| Pollock, J | 1 |
| Goddard, J | 1 |
| Webb, DJ | 1 |
| Lu, TM | 1 |
| Chung, MY | 1 |
| Lin, CC | 1 |
| Hsu, CP | 1 |
| Lin, SJ | 1 |
| Barreto, DV | 1 |
| Liabeuf, S | 1 |
| Glorieux, G | 1 |
| Eloot, S | 1 |
| Barreto, FC | 1 |
| Massy, Z | 2 |
| Vanholder, R | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Ghiadoni, L | 1 |
| Tripepi, G | 1 |
| Bruno, RM | 1 |
| Mancia, G | 1 |
| Baylis, C | 3 |
| Wilcox, CS | 2 |
| Celik, M | 1 |
| Iyisoy, A | 1 |
| Celik, T | 1 |
| Yuksel, UC | 1 |
| Aldámiz-Echevarría, L | 1 |
| Andrade, F | 1 |
| Huang, CF | 1 |
| Chien, SJ | 1 |
| Lin, YJ | 1 |
| Klein, G | 1 |
| Graf, S | 1 |
| Saran, R | 1 |
| Novak, JE | 1 |
| Desai, A | 1 |
| Abdulhayoglu, E | 1 |
| Warren, JS | 1 |
| Bustami, R | 1 |
| Handelman, GJ | 1 |
| Barbato, D | 1 |
| Weitzel, W | 1 |
| D'Alecy, LG | 1 |
| Rajagopalan, S | 1 |
| O'Riordan, E | 1 |
| Chen, J | 1 |
| Brodsky, SV | 1 |
| Smirnova, I | 1 |
| Li, H | 1 |
| Goligorsky, MS | 1 |
| Kronenberg, F | 1 |
| Morath, C | 1 |
| Ritz, E | 1 |
| Vallance, P | 1 |
| Leiper, J | 1 |
| Cakir, E | 2 |
| Ozgurtas, T | 1 |
| Aydin, A | 1 |
| Ozcan, O | 1 |
| Acikel, C | 2 |
| Tasar, M | 1 |
| Genctoy, G | 1 |
| Erbil, K | 1 |
| Kaya, A | 1 |
| Bilgi, C | 1 |
| Oktenli, C | 1 |
| Matsuguma, K | 1 |
| Shibata, R | 1 |
| Matsuoka, H | 1 |
| Imaizumi, T | 1 |
| Wilcken, DE | 1 |
| Sim, AS | 1 |
| Wang, J | 1 |
| Wang, XL | 1 |
| Yamagishi, SI | 1 |
| Schiffrin, EL | 1 |
| Lipman, ML | 1 |
| Mann, JF | 1 |
| Palm, F | 1 |
| Onozato, ML | 1 |
| Luo, Z | 1 |
| Coluzzi, G | 2 |
| Santucci, E | 2 |
| Marzo, F | 1 |
| Andreotti, F | 2 |
| Stenvinkel, P | 1 |
| Carrero, JJ | 1 |
| Lindholm, B | 1 |
| Heimbürger, O | 1 |
| Rodionov, RN | 1 |
| Lentz, SR | 1 |
| Frölich, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease[NCT00384618] | Phase 4 | 100 participants | Interventional | 2001-05-31 | Terminated | ||
| Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia[NCT00011648] | 986 participants (Actual) | Observational | 2008-02-19 | Completed | |||
| Effect of Paricalcitol on Endothelial Function in Chronic Kidney Disease (CKD) Patients (the PENNY Study)[NCT01680198] | Phase 3 | 88 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial[NCT00720967] | Phase 3 | 450 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)[NCT01796418] | 102 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | |||
| A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease[NCT00818792] | Phase 2 | 215 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for n(g),n(g')-dimethyl-l-arginine and Kidney Diseases
| Article | Year |
|---|---|
AGXT2: An unnegligible aminotransferase in cardiovascular and urinary systems.
Topics: Animals; Arginine; Cardiovascular Diseases; Cardiovascular System; Humans; Kidney Diseases; Transami | 2017 |
Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Humans; Kidney Diseases; Water | 2014 |
Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Topics: Arginine; Cardiovascular Diseases; Humans; Kidney Diseases; Kidney Transplantation; Nitric Oxide; Ni | 2015 |
[Endothelial injury and CKD].
Topics: Animals; Arginine; Cardiovascular Diseases; Chronic Disease; Endothelium, Vascular; Humans; Kidney D | 2008 |
[Novelties in the field of progression factors in chronic kidney disease].
Topics: Adult; Amidohydrolases; Animals; Arginine; Carbon; Cardiovascular Diseases; Chronic Disease; Clinica | 2008 |
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Chronic Disease; Disease Progression; Genetic Therap | 2008 |
Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease.
Topics: Adrenergic Antagonists; Angiotensins; Arginine; Diabetes Complications; Humans; Hydroxymethylglutary | 2011 |
Nitric oxide synthase derangements and hypertension in kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Chronic Disease; Disease Progression; Humans; Hypertension; Kidn | 2012 |
Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.
Topics: Animals; Arginine; Cardiovascular Diseases; Disease Models, Animal; Endothelium, Vascular; Humans; K | 2012 |
Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
Topics: Adult; Amidohydrolases; Arginine; Biomarkers; Cardiovascular Diseases; Child; Disease Progression; E | 2012 |
Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease?
Topics: Arginine; Cardiovascular Diseases; Humans; Kidney Diseases; Risk Factors | 2003 |
Functional changes in the ageing kidney: is there a role for asymmetric dimethylarginine?
Topics: Adult; Aged; Aging; Arginine; Enzyme Inhibitors; Humans; Kidney; Kidney Diseases | 2003 |
Endothelial cell dysfunction: the syndrome in making.
Topics: Animals; Apoptosis; Arginine; Cardiovascular Diseases; Cellular Senescence; Endothelium, Vascular; G | 2005 |
Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Cardiovascular Diseases; Carotid Arteries; Carotid S | 2005 |
Biomarkers in chronic kidney disease: utility and issues towards better understanding.
Topics: Animals; Arginine; Biomarkers; C-Reactive Protein; Chronic Disease; Disease Progression; Glomerular | 2005 |
Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Topics: Absorption; Amidohydrolases; Arginine; Biological Availability; Cardiovascular Diseases; Chronic Dis | 2006 |
The past, presence and future of ADMA in nephrology.
Topics: Arginine; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Kidney Diseases; Kidney Function Tests | 2007 |
Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Topics: Arginine; Citrulline; Dietary Supplements; Hepatocytes; Homocysteine; Humans; Kidney Diseases; Liver | 2007 |
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Topics: Arginine; Cardiovascular Diseases; Chronic Disease; Endothelium, Vascular; Humans; Kidney Diseases; | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Nitric oxide deficiency in chronic kidney disease.
Topics: Arginine; Chronic Disease; Humans; Kidney Diseases; Nitric Oxide; Nitric Oxide Synthase | 2008 |
Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
Topics: Amidohydrolases; Animals; Arginine; Cardiovascular Diseases; Diabetes Mellitus; Endothelium-Dependen | 2007 |
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?
Topics: Albuminuria; Arginine; Cardiovascular Diseases; Chronic Disease; Endothelium, Vascular; Humans; Kidn | 2008 |
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?
Topics: Animals; Arginine; Arteriosclerosis; Enzyme Inhibitors; Humans; Kidney Diseases; Nitric Oxide Syntha | 2001 |
3 trials available for n(g),n(g')-dimethyl-l-arginine and Kidney Diseases
| Article | Year |
|---|---|
Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
Topics: Adult; Aged; Anticholesteremic Agents; Arginine; Carotid Arteries; Chronic Disease; Creatinine; Doub | 2009 |
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cho | 2010 |
Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.
Topics: Adult; Aged; alpha-Tocopherol; Antioxidants; Arginine; Chronic Disease; Female; Humans; Kidney; Kidn | 2003 |
34 other studies available for n(g),n(g')-dimethyl-l-arginine and Kidney Diseases
| Article | Year |
|---|---|
A Therapeutic Extracorporeal Device for Specific Removal of Pathologic Asymmetric Dimethylarginine from the Blood.
Topics: Animals; Arginine; Kidney Diseases; Swine | 2022 |
Intradialytic hypotension: beyond hemodynamics.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme 2; Arginine; Biomarkers; Blood P | 2019 |
Renal asymmetric dimethylarginine inhibits fibrosis.
Topics: Amidohydrolases; Animals; Arginine; Disease Models, Animal; Fibronectins; Fibrosis; Kidney; Kidney D | 2020 |
Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice.
Topics: Aging; Aldosterone; Amidohydrolases; Animals; Arginine; Cell Line; Creatinine; Diabetes Mellitus, Ex | 2017 |
Effects of propolis, caffeic acid phenethyl ester, and pollen on renal injury in hypertensive rat: An experimental and theoretical approach.
Topics: Animals; Antioxidants; Arginine; Aryldialkylphosphatase; Binding Sites; Caffeic Acids; Glutathione R | 2017 |
Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys.
Topics: Animals; Arginine; Cell Line; Gene Expression Regulation, Enzymologic; Humans; Kidney Diseases; Male | 2019 |
Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers.
Topics: Animals; Arginine; Blotting, Western; Electron Spin Resonance Spectroscopy; Female; Hypertension; Ki | 2013 |
Increased serum asymmetric dimethylarginine level is an independent predictor of contrast-induced nephropathy.
Topics: Aged; Angina Pectoris; Arginine; Contrast Media; Coronary Angiography; Creatinine; Female; Humans; K | 2013 |
Cardiovascular-renal changes after kidney donation: one-year follow-up study.
Topics: Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Female; Follow-Up Studies; Glomerular Fi | 2015 |
Coronary artery calcification, ADMA, and insulin resistance in CKD patients.
Topics: Aged; Arginine; Calcinosis; Case-Control Studies; Chronic Disease; Coronary Angiography; Coronary Ar | 2008 |
Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
Topics: Arginine; Cardiovascular Diseases; Carotid Arteries; Humans; Kidney Diseases; Kidney Failure, Chroni | 2009 |
Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death.
Topics: Anemia, Sickle Cell; Arginine; Case-Control Studies; Citrulline; Follow-Up Studies; Hemolysis; Human | 2009 |
Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients.
Topics: Adult; Arginine; Cardiovascular Diseases; Graft Rejection; Humans; Kidney Diseases; Kidney Transplan | 2010 |
Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
Topics: Adult; Aged; Angiopoietin-2; Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Ch | 2010 |
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arginine; Chronic Disease; Diabetic Nephropat | 2010 |
FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.
Topics: Adult; Arginine; Chronic Disease; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fo | 2010 |
Bile duct ligation in developing rats: temporal progression of liver, kidney, and brain damage.
Topics: Animals; Arginine; Bile Ducts; Brain; Brain Diseases; Cholestasis; Disease Progression; End Stage Li | 2010 |
Do sea stars have low ADMA levels? High ADMA and low EPC count--duo infernal for the kidney.
Topics: Animals; Arginine; Cell Count; Chronic Disease; Endothelial Cells; Glomerular Filtration Rate; Human | 2010 |
Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Brachial Artery; C-Reactive Prote | 2011 |
Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Albuminuria; Arginine; Biomarkers; Chi-Square Distribution; Chromatography, | 2011 |
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Arginine; Belgium; Biomarkers; Case-Control Studies; Cell L | 2011 |
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Chronic Disease; Cross-Sectional Studies; Disease Pro | 2011 |
The relationship between L-arginine/ADMA ratio and coronary collateral development in patients with low glomerular filtration rate.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Chi-Square Distribution; Collateral Circulatio | 2012 |
Aminoguanidine attenuates hypertension, whereas 7-nitroindazole exacerbates kidney damage in spontaneously hypertensive rats: the role of nitric oxide.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Citrulline; Guanidines; Hypertension; Indazoles; | 2013 |
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure.
Topics: Aged; Arginine; Endothelium, Vascular; Heart Failure; Humans; Kidney Diseases; Male; Renal Circulati | 2003 |
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Topics: Adult; Arginine; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Hemoglobins; H | 2005 |
Asymmetric dimethylarginine and kidney disease--marker or mediator?
Topics: Animals; Arginine; Biomarkers; Humans; Kidney; Kidney Diseases; Nitric Oxide; Renal Insufficiency; R | 2005 |
The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.
Topics: Adult; Arginine; Brachial Artery; Cardiovascular Diseases; Chronic Disease; Copper; Endothelium, Vas | 2006 |
ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease.
Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; Chronic Disease; Disease Prog | 2006 |
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Capillaries; Chronic Disease; Disease Models, Animal; Disease Pr | 2007 |
A new perspective for the treatment of renal diseases?
Topics: Amidohydrolases; Arginine; Cardiovascular Diseases; Chronic Disease; Humans; Kidney Diseases; Nitric | 2007 |
Asymmetric dimethylarginine and impaired cardiovascular healing.
Topics: Apoptosis; Arginine; Cardiovascular Diseases; Humans; Kidney Diseases; Myocardial Ischemia; Nitric O | 2009 |
Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine.
Topics: Acetylcysteine; Angioplasty, Balloon, Coronary; Antioxidants; Arginine; Biomarkers; Contrast Media; | 2007 |
The homocysteine paradox.
Topics: Animals; Arginine; Cardiovascular Diseases; Cystatin C; Cystatins; Disease Models, Animal; Folic Aci | 2008 |